ASCO 2022 | CodeBreaK100: detecting mechanisms of intrinsic resistance by ctDNA

Bob T. Li, MD, MPH, Memorial Sloan Kettering Cancer Center, New York, NY, discusses findings from the Phase I/II CodeBreaK100 (NCT03600883) of sotorasib in patients with KRAS p.G12C-mutated non–small cell lung cancer (NSCLC) and colorectal cancer (CRC) who have received one prior line of therapy. The objective response rate was 41% and 12% in patients with NSCLC and CRC respectively and the progression-free survival was 6 and 4 months respectively. The two-year overall survival rate was 33% in patients with NSCLC, demonstrating a robust response. Dr Li additionally highlights the use of circulating tumor DNA (ctDNA) to elucidate mechanisms of drug resistance. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.